Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Combinations and uses thereof
US11224654B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11224654-B2 |
| Application number | US-201615752009-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 18, 2016 |
| Priority date | Aug 21, 2015 |
| Publication date | Jan 18, 2022 |
| Grant date | Jan 18, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
First claim
Opening claim text (preview).
We claim: 1. A method for treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in a patient in need thereof, said method comprising administering to the patient an antibody specific for CD19, wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6), a heavy chain constant domain of the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVV HQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY PSDIAVEWESNGQENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 12), and a light chain constant domain of the sequence RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13), and idelalisib. 2. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered separately. 3. The method of claim 2 , wherein said antibody specific for CD19 and idelalisib are administered separately physically. 4. The method of claim 2 , wherein said antibody specific for CD19 and idelalisib are administered separately in time. 5. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered together. 6. The method of claim 1 , wherein idelalisib is administered prior to administration of the antibody specific for CD19. 7. The method of claim 1 , wherein idelalisib is administered after administration of the antibody specific for CD19. 8. The method of claim 1 wherein the antibody specific for CD19 comprises a variable heavy chain of the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11). 9. The method of claim 1 , wherein the patient has non-Hodgkin's lymphoma. 10. The method of claim 9 , wherein the non-Hodgkin's lymphoma is follicular lymphoma. 11. The method of claim 9 , wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma. 12. The method of claim 9 , wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma. 13. The method of claim 9 , wherein the non-Hodgkin's lymphoma is marginal zone lymphoma. 14. The method of claim 9 , wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma. 15. The method of claim 9 , wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma. 16. The method of claim 9 , wherein the non-Hodgkin's lymphoma is mantle cell lymphoma. 17. The method of claim 1 , wherein the patient has chronic lymphocytic leukemia. 18. The method of claim 1 , wherein the patient has acute lymphoblastic leukemia.
Assignees
Inventors
Classifications
Purines, e.g. adenine · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
- A61K45/06Primary
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11224654B2 cover?
- The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
- Who is the assignee on this patent?
- Morphosys Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).